



Medicines Australia Community Chest (MACC) 2014 - 2015

The Medicines Australia Community Chest (MACC) represents a strategic collaboration between Arthritis Australia and the participating Medicines Australia member companies listed below:

AbbVie Pty Ltd

www.abbvie.com.au

AstraZeneca

www.astrazeneca.com.au

Janssen

www.janssen.com.au

Eli Lilly Australia Pty Ltd

www.lilly.com.ua

Pfizer Australia Pty Limited

www.pfizer.com.au

Roche Products Pty Limited

www.roche-australia.com

The collaboration operates in accordance with the principles in the 'Working Together Guide' jointly developed by the Consumers Health Forum of Australia and Medicines Australia (<https://medicinesaustralia.com.au/wp-content/uploads/sites/52/2015/08/Working-Together-Brochure-2015.pdf>)

By bringing together members of leading pharmaceutical companies, the MACC supports projects aimed at improving the health outcomes of Australians through evidence-based management of arthritis. Since its inception in 2006, initiatives have included:

- Arthritis and Disability Study (launched end 2014)
- The Voice of GPs on Arthritis (companion to The Voice of Arthritis 2012)
- The Voice of Arthritis (social impact study 2004)
- Painful Realities: The economic impact of arthritis in Australia (Access Economics study 2007)
- Arthritis: The Bottom Line (Access Economics study 2005)
- Development, review and production of 10 steps for living well with arthritis booklet

[These resources are available on-line – [10 steps](#) and [reports](#)]

For the 2013-14 project the MACC has provided \$175,000.